The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC)

European Journal of Cancer

Volumn 41, Issue 11, 2005, Pages 1542-1546

  Ng, Matthew ^a   Cunningham, David ^a   Norman, Andrew R ^a,b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

5 fluorouracil; Angina; Capecitabine; Cardiotoxicity; Oxaliplatin; Ralitrexed; Thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; CAPECITABINE; FLUOROURACIL; OXALIPLATIN; RALTITREXED; TROPONIN I;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ADVANCED CANCER; AGED; ANGINA PECTORIS; ARTICLE; AWARENESS; CARDIOTOXICITY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HEART FAILURE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PATIENT; PHYSICIAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SAMPLE SIZE; SIDE EFFECT; ST SEGMENT DEPRESSION; SUDDEN DEATH; THROMBOEMBOLISM; TREATMENT WITHDRAWAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; ORGANOPLATINUM COMPOUNDS; PROSPECTIVE STUDIES; RISK FACTORS; THROMBOEMBOLISM;

EID: 22144479717     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.03.027     Document Type: Article

References (26)

1. A. Roth, K. Kolaric, and S. Popovic Letter: cardiotoxicity of 5-fluorouracil (NSC-19893) Cancer Chemother Rep 59 6 1975 1051 1052
2. C.C. Meyer, K.A. Calis, and L.B. Burke Symptomatic cardiotoxicity associated with 5-fluorouracil Pharmacotherapy 17 4 1997 729 736
3. M. de Forni, M.C. Malet-Martino, and P. Jaillais Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study J Clin Oncol 10 11 1992 1795 1801
4. S.S. Akhtar, K.P. Salim, and Z.A. Bano Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: a prospective study Oncology 50 6 1993 441 444
5. D.L. Keefe, N. Roistacher, and M.K. Pierri Clinical cardiotoxicity of 5-fluorouracil J Clin Pharmacol 33 11 1993 1060 1070
6. R. Labianca, G. Beretta, and M. Clerici Cardiotoxicity of 5-flurouracil: a study of 1083 patients Tumori 68 1982 505 510
7. N.C. Robben, A.W. Pippas, and J.O. Moore The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy Cancer 71 2 1993 493 509
8. M. Mackean, A. Planting, and C. Twelves Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer J Clin Oncol 16 9 1998 2977 2985
9. P.M. Hoff, R. Ansari, and G. Batist Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study J Clin Oncol 19 8 2001 2282 2292
10. E. Van Cutsem, C. Twelves, and J. Cassidy Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study J Clin Oncol 19 21 2001 4097 4106
11. M.M. Borner, D. Dietrich, and R. Stupp Phase II study of capecitabine and oxaliplatin in first-and second-line treatment of advanced or metastatic colorectal cancer J Clin Oncol 20 7 2002 1759 1766
12. W. Scheithauer, G.V. Kornek, and M. Raderer Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 21 7 2003 1307 1312
13. R.M. Goldberg, D.J. Sargent, and R.F. Morton A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer J Clin Oncol 22 1 2004 23 30
14. M.L. Rothenberg, A.M. Oza, and R.H. Bigelow Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial J Clin Oncol 21 11 2003 2059 2069
15. N. Frickhofen, F.J. Beck, and B. Jung Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil Ann Oncol 13 5 2002 797 801
16. A. Bertolini, M. Flumano, and O. Fusco Acute cardiotoxicity during capecitabine treatment: a case report Tumori 87 3 2001 200 206
17. E. Van Cutsem, P.M. Hoff, and J.L. Blum Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil Ann Oncol 13 3 2002 484 485
18. L.K. Shoemaker, U. Arora, and C.M. Rocha Lima 5-Fluorouracil-induced coronary vasospasm Cancer Control 11 1 2004 46 49
19. T. Sudhoff, M.D. Enderle, and M. Pahlke 5-Fluorouracil induces arterial vasocontractions Ann Oncol 15 4 2004 661 664
20. K. Becker, J.F. Erckenbrecht, and D. Haussinger Cardiotoxicity of the antiproliferative compound fluorouracil Drugs 57 4 1999 475 484
21. S. Rezkalla, R.A. Kloner, and J. Ensley Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study J Clin Oncol 7 4 1989 509 514
22. A.M. Grandi, G. Pinotti, and E. Morandi Noninvasive evaluation of cardiotoxicity of 5-fluorouracil and low doses of folinic acid: a one-year follow-up study Ann Oncol 8 7 1997 705 708
23. Z. Sasson, C.D. Morgan, and B. Wang 5-Fluorouracil related toxic myocarditis: case reports and pathological confirmation Can J Cardiol 10 8 1994 861 864
24. H. Koenig, and A. Patel Biochemical basis for fluorouracil neurotoxicity. The role of Krebs cycle inhibition by fluoroacetate Arch Neurol 23 2 1970 155 160
25. C. Haskel Drugs used in cancer chemotherapy CM Haskel Cancer treatment 2nd ed. 1984 Saunders Philadelphia 43 106
26. T. Kuzel, B. Esparaz, and D. Green Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin Cancer 65 4 1990 885 889